Skip Navigation



Annals of Oncology Advance Access published online on January 31, 2005
Annals of Oncology, doi:10.1093/annonc/mdi120
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/4/597    most recent
mdi120v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Camps, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camps, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received September 21, 2004
Revised November 25, 2004
Accepted November 29, 2004

Article

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

C. Camps 1*, E. Felip 2, J. M. Sanchez 3, B. Massuti 4, A. Artal 5, L. Paz-Ares 6, A. Carrato 7, V. Alberola 8, A. Blasco 1, J. Baselga 2, L. Astier 9, M. Voi 9, R. Rosell 3, and On behalf of the Spanish Lung Cancer Group

1 Hospital General Universitario de Valencia, Valencia, Spain
2 Hospital Vall d'Hebrón, Barcelona, Spain
3 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
4 Hospital General de Alicante, Alicante, Spain
5 Hospital Miguel Servet, Zaragoza, Spain
6 Hospital Universitario Doce de Octubre, Madrid, Spain
7 Hospital General de Elche, Alicante, Spain
8 Hospital Arnau de Vilanova, Valencia, Spain
9 Bristol-Myers Squibb-Europe, Waterloo, Belgium

* To whom correspondence should be addressed.
C. Camps, E-mail: camps_car{at}gva.es


  Abstract

Background: The purpose of this study was to evaluate the tolerability and efficacy of BMS-184476, an analog of paclitaxel, in patients with advanced non-small-cell lung cancer (NSCLC) progressing or relapsing following at least one prior chemotherapy regimen.

Patients and methods: Fifty-six previously treated advanced NSCLC patients received BMS-184476 at a dose of 60 mg/m2 administered intravenously over 1 h every 21 days.

Results: The median number of cycles delivered per patient was five (range one to 17). Dose reduction was required in only 3.8% of cycles. Grade 4 neutropenia occurred in 19.6% of patients, but no grade 4 thrombocytopenia or anemia was reported. Febrile neutropenia was observed in only two (3.6%) patients and there were no life-threatening events. Grade 3/4 peripheral sensory-motor neuropathy was reported in 9% of patients. Other non-hematological toxicities, such as nausea and vomiting, myalgia and arthralgia, diarrhea, and mucositis, were uncommon. Partial responses were observed in eight (14.3%) patients and stable disease in 33 (58.9%). Median progression-free survival was 3.7 months [95% confidence interval (CI) 2.7-5.4] and median overall survival was 10 months (95% CI 6-13.4).

Conclusions: BMS-184476 was well tolerated at the dose of 60 mg/m2 and showed evidence of antitumor activity in previously treated NSCLC.

Keywords: BMS-184476; novel taxane; NSCLC; second-line chemotherapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.